A	O
PMLRARalpha	B-DNA
transgene	I-DNA
initiates	O
murine	O
acute	O
promyelocytic	O
leukemia	O
.	O

The	O
malignant	B-cell_type
cells	I-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	O
)	O
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B-protein
PMLRAR	I-protein
alpha	I-protein
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	B-DNA
alpha	I-DNA
cDNA	I-DNA
in	O
myeloid	B-cell_type
cells	I-cell_type
of	O
transgenic	O
mice	O
.	O

PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O

Both	O
the	O
preleukemic	O
state	O
and	O
the	O
leukemia	O
could	O
be	O
transplanted	O
to	O
nontransgenic	O
mice	O
,	O
and	O
the	O
transplanted	O
preleukemia	O
could	O
progress	O
to	O
APL	O
.	O

The	O
APL	O
recapitulated	O
features	O
of	O
the	O
human	O
disease	O
,	O
including	O
a	O
response	O
to	O
retinoic	O
acid	O
.	O

Retinoic	O
acid	O
caused	O
the	O
leukemic	B-cell_type
cells	I-cell_type
to	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
eliciting	O
remissions	O
of	O
both	O
the	O
preleukemic	O
state	O
and	O
APL	O
in	O
mice	O
.	O

Our	O
results	O
demonstrate	O
that	O
PMLRAR	B-protein
alpha	I-protein
impairs	O
neutrophil	O
differentiation	O
and	O
initiates	O
the	O
development	O
of	O
APL	O
.	O

The	O
transgenic	O
mice	O
described	O
here	O
provide	O
an	O
apparently	O
accurate	O
model	O
for	O
human	O
APL	O
that	O
includes	O
clear	O
evidence	O
of	O
tumor	O
progression	O
.	O

The	O
model	O
should	O
be	O
useful	O
for	O
exploring	O
the	O
molecular	O
pathogenesis	O
of	O
APL	O
and	O
the	O
mechanisms	O
of	O
the	O
therapeutic	O
response	O
to	O
retinoic	O
acid	O
,	O
as	O
well	O
as	O
for	O
preclinical	O
studies	O
of	O
therapeutic	O
regimens	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

94	NULL
,	NULL
pp	NULL
.	NULL

2551-2556	NULL
,	NULL
March	NULL
1997	NULL
Medical	NULL
Sciences	NULL
A	NULL
PMLRARa	NULL
transgene	NULL
initiates	NULL
murine	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
[	NULL
retinoic	NULL
acid	NULL
/t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
/transgenic	NULL
mice	NULL
/hematopoiesis	NULL
]	NULL
DIanE	NULL
Scorr	NULL
Kogan*	NULL
$	NULL
,	NULL
Eric	NULL
LagassE	NULL
$	NULL
§	NULL
,	NULL
Irving	NULL
WEirssman	NULL
$	NULL
§	NULL
,	NULL
MyRIAM	NULL
ALcaLay	NULL
``	NULL
,	NULL
PIER	NULL
GIUSEPPE	NULL
PELICCIN	NULL
,	NULL
SUSAN	NULL
ATWATER	NULL
!	NULL

!	NULL

,	NULL
AnD	NULL
J.	NULL
MIcHAEL	NULL
BisHop*1**tt	NULL
*G.	NULL
W.	NULL
Hooper	NULL
Foundation	NULL
and	NULL
Departments	NULL
of	NULL
*Biochemistry	NULL
and	NULL
Biophysics	NULL
and	NULL
**Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
94143-0552	NULL
;	NULL
Departments	NULL
of	NULL
Pathology	NULL
and	NULL
Developmental	NULL
Biology	NULL
,	NULL
Beckman	NULL
Center	NULL
B261	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305	NULL
;	NULL
Department	NULL
of	NULL
Experimental	NULL
Oncology	NULL
,	NULL
European	NULL
Institute	NULL
of	NULL
Oncology	NULL
,	NULL
Via	NULL
Ripamonti	NULL
,	NULL
435-20141	NULL
Milan	NULL
,	NULL
Italy	NULL
;	NULL
and	NULL
Department	NULL
of	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
94143-0100	NULL
Contributed	NULL
by	NULL
J.	NULL
Michael	NULL
Bishop	NULL
,	NULL
December	NULL
31	NULL
,	NULL
1996	NULL
ABSTRACT	NULL
The	NULL
malignant	NULL
cells	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
contain	NULL
a	NULL
reciprocal	NULL
chromosomal	NULL
translocation	NULL
that	NULL
fuses	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
(	NULL
PML	NULL
)	NULL
with	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
(	NULL
RARa	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
chimera	NULL
PMLRARa	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
leukemogenesis	NULL
,	NULL
we	NULL
expressed	NULL
a	NULL
PMLRARa	NULL
cDNA	NULL
in	NULL
myeloid	NULL
cells	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

PMLRARa	NULL
transgenic	NULL
mice	NULL
exhibited	NULL
impaired	NULL
neutrophil	NULL
maturation	NULL
early	NULL
in	NULL
life	NULL
,	NULL
which	NULL
progressed	NULL
at	NULL
a	NULL
low	NULL
frequency	NULL
over	NULL
the	NULL
course	NULL
of	NULL
several	NULL
months	NULL
to	NULL
overt	NULL
APL	NULL
.	NULL

Both	NULL
the	NULL
preleukemic	NULL
state	NULL
and	NULL
the	NULL
leukemia	NULL
could	NULL
be	NULL
transplanted	NULL
to	NULL
nontransgenic	NULL
mice	NULL
,	NULL
and	NULL
the	NULL
transplanted	NULL
preleukemia	NULL
could	NULL
progress	NULL
to	NULL
APL	NULL
.	NULL

The	NULL
APL	NULL
recapitulated	NULL
features	NULL
of	NULL
the	NULL
human	NULL
disease	NULL
,	NULL
including	NULL
a	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
.	NULL

Retinoic	NULL
acid	NULL
caused	NULL
the	NULL
leukemic	NULL
cells	NULL
to	NULL
differentiate	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
eliciting	NULL
remissions	NULL
of	NULL
both	NULL
the	NULL
preleukemic	NULL
state	NULL
and	NULL
APL	NULL
in	NULL
mice	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
PMLRARa	NULL
impairs	NULL
neutrophil	NULL
differentiation	NULL
and	NULL
initiates	NULL
the	NULL
development	NULL
of	NULL
APL	NULL
.	NULL

The	NULL
transgenic	NULL
mice	NULL
described	NULL
here	NULL
provide	NULL
an	NULL
apparently	NULL
accurate	NULL
model	NULL
for	NULL
human	NULL
APL	NULL
that	NULL
includes	NULL
clear	NULL
evidence	NULL
of	NULL
tumor	NULL
progression	NULL
.	NULL

The	NULL
model	NULL
should	NULL
be	NULL
useful	NULL
for	NULL
exploring	NULL
the	NULL
molecular	NULL
pathogenesis	NULL
of	NULL
APL	NULL
and	NULL
the	NULL
mechanisms	NULL
of	NULL
the	NULL
therapeutic	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
,	NULL
as	NULL
well	NULL
as	NULL
for	NULL
preclinical	NULL
studies	NULL
of	NULL
therapeutic	NULL
regimens	NULL
.	NULL

The	NULL
malignant	NULL
cells	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
carry	NULL
a	NULL
reciprocal	NULL
chromosomal	NULL
translocation	NULL
,	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
(	NULL
q24	NULL
;	NULL
q21	NULL
)	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

The	NULL
translocation	NULL
fuses	NULL
two	NULL
genes	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
:	NULL
RARa	NULL
,	NULL
which	NULL
encodes	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
«	NULL
(	NULL
Rara	NULL
)	NULL
;	NULL
and	NULL
promelocytic	NULL
leukemia	NULL
(	NULL
PML	NULL
)	NULL
,	NULL
which	NULL
encodes	NULL
Pml	NULL
,	NULL
a	NULL
nuclear	NULL
phosphoprotein	NULL
of	NULL
unknown	NULL
function	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Prior	NULL
to	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
genes	NULL
at	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
breakpoint	NULL
,	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
ATRA	NULL
)	NULL
had	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
complete	NULL
remission	NULL
in	NULL
APL	NULL
patients	NULL
by	NULL
differentiation	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

This	NULL
convergence	NULL
of	NULL
a	NULL
novel	NULL
therapeutic	NULL
strategy	NULL
and	NULL
the	NULL
molecular	NULL
analysis	NULL
of	NULL
the	NULL
translocation	NULL
focused	NULL
interest	NULL
on	NULL
how	NULL
the	NULL
resulting	NULL
PMLRARa	NULL
«	NULL
and	NULL
RARaPML	NULL
fusion	NULL
genes	NULL
functioned	NULL
in	NULL
the	NULL
pathogenesis	NULL
and	NULL
therapeutic	NULL
response	NULL
of	NULL
APL	NULL
.	NULL

The	NULL
PMLRARa	NULL
fusion	NULL
encodes	NULL
the	NULL
bulk	NULL
of	NULL
both	NULL
gene	NULL
products	NULL
.	NULL

PmlRara	NULL
retains	NULL
activities	NULL
of	NULL
both	NULL
Pml	NULL
and	NULL
Rara	NULL
,	NULL
including	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
retinoic	NULL
acid	NULL
,	NULL
and	NULL
can	NULL
inhibit	NULL
differentiation	NULL
of	NULL
cultured	NULL
cells	NULL
(	NULL
5	NULL
,	NULL
9-18	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
coding	NULL
domain	NULL
of	NULL
the	NULL
reciprocal	NULL
RARaPML	NULL
fusion	NULL
contains	NULL
little	NULL
of	NULL
note	NULL
and	NULL
has	NULL
not	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
any	NULL
phenotypic	NULL
effects	NULL
.	NULL

While	NULL
PMLRARa	NULL
is	NULL
expressed	NULL
in	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

Copyright	NULL
©	NULL
1997	NULL
by	NULL
Tar	NULL
Narronat	NULL
Acapemy	NULL
or	NULL
Sciences	NULL
or	NULL
THE	NULL
USA	NULL
0027-8424	NULL
/97/942551-6	NULL
$	NULL
2.00/0	NULL
PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
http	NULL
:	NULL
//www.pnas.org	NULL
.	NULL

2551	NULL
virtually	NULL
all	NULL
cases	NULL
of	NULL
APL	NULL
,	NULL
RARaPML	NULL
is	NULL
frequently	NULL
not	NULL
expressed	NULL
(	NULL
19	NULL
)	NULL
.	NULL

For	NULL
these	NULL
reasons	NULL
it	NULL
has	NULL
been	NULL
assumed	NULL
that	NULL
PMLRARa	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
initiation	NULL
of	NULL
leukemogenesis	NULL
,	NULL
but	NULL
this	NULL
view	NULL
has	NULL
not	NULL
been	NULL
directly	NULL
authenticated	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
the	NULL
establishment	NULL
of	NULL
a	NULL
transgenic	NULL
mouse	NULL
model	NULL
that	NULL
documents	NULL
the	NULL
ability	NULL
of	NULL
PMLRARa	NULL
to	NULL
initiate	NULL
leukemogenesis	NULL
.	NULL

The	NULL
mice	NULL
develop	NULL
two	NULL
apparently	NULL
unrelated	NULL
abnormalities	NULL
.	NULL

The	NULL
first	NULL
is	NULL
a	NULL
severe	NULL
papillomatosis	NULL
of	NULL
the	NULL
skin	NULL
that	NULL
we	NULL
will	NULL
describe	NULL
elsewhere	NULL
.	NULL

The	NULL
second	NULL
is	NULL
a	NULL
disturbance	NULL
of	NULL
hematopoiesis	NULL
that	NULL
presented	NULL
as	NULL
a	NULL
partial	NULL
block	NULL
of	NULL
differentiation	NULL
in	NULL
the	NULL
neutrophil	NULL
lineage	NULL
of	NULL
the	NULL
transgenic	NULL
mice	NULL
and	NULL
then	NULL
progressed	NULL
at	NULL
low	NULL
frequency	NULL
to	NULL
overt	NULL
APL	NULL
.	NULL

The	NULL
leukemias	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
faithful	NULL
reproduction	NULL
of	NULL
the	NULL
human	NULL
disease	NULL
,	NULL
including	NULL
a	NULL
therapeutic	NULL
response	NULL
to	NULL
ATRA	NULL
that	NULL
reflects	NULL
differentiation	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
.	NULL

Both	NULL
the	NULL
preleukemic	NULL
state	NULL
and	NULL
the	NULL
overt	NULL
leukemia	NULL
can	NULL
be	NULL
transplanted	NULL
into	NULL
nontransgenic	NULL
hosts	NULL
.	NULL

The	NULL
mouse	NULL
model	NULL
described	NULL
here	NULL
can	NULL
be	NULL
used	NULL
to	NULL
explore	NULL
the	NULL
pathogenesis	NULL
and	NULL
treatment	NULL
of	NULL
APL	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Generation	NULL
of	NULL
Transgenic	NULL
Mice	NULL
.	NULL

A	NULL
human	NULL
PMLRARa	NULL
cDNA	NULL
(	NULL
10	NULL
)	NULL
[	NULL
whose	NULL
chromosome	NULL
15	NULL
breakpoint	NULL
lies	NULL
in	NULL
breakpoint	NULL
cluster	NULL
region	NULL
1	NULL
as	NULL
defined	NULL
in	NULL
Pandolfi	NULL
1992	NULL
(	NULL
20	NULL
)	NULL
]	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
hMRPS8	NULL
expression	NULL
cassette	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Transgenic	NULL
animals	NULL
were	NULL
prepared	NULL
following	NULL
standard	NULL
procedures	NULL
(	NULL
22	NULL
)	NULL
from	NULL
inbred	NULL
FVB/N	NULL
mice	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
Cells	NULL
from	NULL
Tissues	NULL
.	NULL

Blood	NULL
was	NULL
obtained	NULL
from	NULL
anesthetized	NULL
animals	NULL
by	NULL
venipuncture	NULL
of	NULL
the	NULL
retro-orbital	NULL
venous	NULL
plexus	NULL
.	NULL

Bone	NULL
marrow	NULL
was	NULL
obtained	NULL
by	NULL
flushing	NULL
buffered	NULL
saline	NULL
through	NULL
mouse	NULL
long	NULL
bones	NULL
.	NULL

Tissues	NULL
were	NULL
suspended	NULL
in	NULL
buffered	NULL
saline	NULL
and	NULL
filtered	NULL
through	NULL
nylon	NULL
mesh	NULL
.	NULL

Red	NULL
cells	NULL
were	NULL
lysed	NULL
as	NULL
necessary	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Blood	NULL
and	NULL
bone	NULL
marrow	NULL
smears	NULL
and	NULL
cytospins	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
standard	NULL
hemato-logical	NULL
techniques	NULL
.	NULL

Immunofluorescence	NULL
.	NULL

Cytospins	NULL
prepared	NULL
as	NULL
above	NULL
were	NULL
fixed	NULL
for	NULL
5	NULL
min	NULL
in	NULL
-20°C	NULL
methanol	NULL
and	NULL
air	NULL
dried	NULL
.	NULL

Samples	NULL
were	NULL
blocked	NULL
for	NULL
15	NULL
min	NULL
in	NULL
PBS	NULL
with	NULL
10	NULL
%	NULL
normal	NULL
goat	NULL
serum	NULL
(	NULL
PBS/NGS	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
rabbit	NULL
polyclonal	NULL
antiserum	NULL
prepared	NULL
against	NULL
a	NULL
glutathione	NULL
S-transferase	NULL
Pml	NULL
fusion	NULL
protein	NULL
diluted	NULL
1:4000	NULL
in	NULL
PBS/NGS	NULL
(	NULL
the	NULL
antiserum	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
K.	NULL
S.	NULL
Chang	NULL
,	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Texas	NULL
)	NULL
.	NULL

Washing	NULL
with	NULL
PBS/NGS	NULL
was	NULL
followed	NULL
by	NULL
30	NULL
min	NULL
of	NULL
incubation	NULL
with	NULL
Texas	NULL
Red-labeled	NULL
goat	NULL
anti-rabbit	NULL
IgG	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
)	NULL
at	NULL
1:400	NULL
in	NULL
PBS/NGS	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
mounted	NULL
in	NULL
Prolong	NULL
Abbreviations	NULL
:	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
PML	NULL
,	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
;	NULL
RARa	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
;	NULL
ATRA	NULL
,	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
;	NULL
DAPI	NULL
,	NULL
4,6-diamidino-2-phenylindole	NULL
;	NULL
FACS	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
.	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

#	NULL
D.B	NULL
.	NULL

and	NULL
S.K	NULL
.	NULL

contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

2552	NULL
Medical	NULL
Sciences	NULL
:	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

medium	NULL
(	NULL
Molecular	NULL
Probes	NULL
)	NULL
plus	NULL
1	NULL
wM	NULL
4,6-diamidino-2-phenylindole	NULL
(	NULL
DAPI	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Fluorescence-Activated	NULL
Cell	NULL
Sorting	NULL
(	NULL
FACS	NULL
)	NULL
.	NULL

Single	NULL
cell	NULL
suspensions	NULL
prepared	NULL
as	NULL
above	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
indicated	NULL
antibodies	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
Flow	NULL
Cytometer	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
mAbs	NULL
for	NULL
20-30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
then	NULL
allowed	NULL
to	NULL
settle	NULL
through	NULL
a	NULL
calf	NULL
serum	NULL
cushion	NULL
to	NULL
remove	NULL
unbound	NULL
antibodies	NULL
.	NULL

Cells	NULL
were	NULL
resuspended	NULL
in	NULL
staining	NULL
medium	NULL
(	NULL
buffered	NULL
saline	NULL
with	NULL
2	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
)	NULL
containing	NULL
propidium	NULL
iodide	NULL
at	NULL
4	NULL
ug/ml	NULL
.	NULL

At	NULL
least	NULL
10,000	NULL
cells	NULL
were	NULL
analyzed	NULL
per	NULL
sample	NULL
.	NULL

Dead	NULL
cells	NULL
that	NULL
stained	NULL
with	NULL
propidium	NULL
iodide	NULL
were	NULL
gated	NULL
out	NULL
at	NULL
the	NULL
time	NULL
of	NULL
analysis	NULL
.	NULL

FACS	NULL
data	NULL
were	NULL
analyzed	NULL
with	NULL
the	NULL
CELLQUEST	NULL
program	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Anti-Gr-1-fluorescein	NULL
isothiocyanate	NULL
and	NULL
an-ti-MAC-1-phycoerythrin	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
.	NULL

MethyIcellulose	NULL
Cultures	NULL
of	NULL
Bone	NULL
Marrow	NULL
.	NULL

Duplicate	NULL
cultures	NULL
of	NULL
5	NULL
X	NULL
10	NULL
%	NULL
viable	NULL
bone	NULL
marrow	NULL
cells	NULL
per	NULL
35-mm	NULL
tissue	NULL
culture	NULL
dish	NULL
were	NULL
incubated	NULL
for	NULL
7	NULL
days	NULL
in	NULL
Methocult	NULL
M3230	NULL
methylcellulose	NULL
medium	NULL
(	NULL
Stem	NULL
Cell	NULL
Technologies	NULL
,	NULL
Vancouver	NULL
,	NULL
British	NULL
Columbia	NULL
)	NULL
supplemented	NULL
with	NULL
2	NULL
%	NULL
pokeweed	NULL
mitogen	NULL
spleen-conditioned	NULL
media	NULL
(	NULL
Stem	NULL
Cell	NULL
Technologies	NULL
)	NULL
with	NULL
or	NULL
without	NULL
1	NULL
uM	NULL
ATRA	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Western	NULL
Blot	NULL
Analysis	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
25	NULL
)	NULL
with	NULL
rabbit	NULL
polyclonal	NULL
antiserum	NULL
raised	NULL
against	NULL
a	NULL
glutathione	NULL
S-transferase	NULL
fusion	NULL
protein	NULL
encompassing	NULL
amino	NULL
acids	NULL
420-462	NULL
of	NULL
the	NULL
human	NULL
Rara	NULL
protein	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Before	NULL
use	NULL
,	NULL
the	NULL
antiserum	NULL
was	NULL
affinity	NULL
purified	NULL
with	NULL
the	NULL
analogous	NULL
maltose	NULL
binding	NULL
protein	NULL
fusion	NULL
.	NULL

Transplantation	NULL
of	NULL
Leukemia	NULL
.	NULL

Viable	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
isolated	NULL
from	NULL
bone	NULL
marrow	NULL
,	NULL
spleen	NULL
,	NULL
or	NULL
lymph	NULL
nodes	NULL
of	NULL
animals	NULL
with	NULL
leukemia	NULL
were	NULL
resuspended	NULL
in	NULL
200	NULL
pl	NULL
of	NULL
buffered	NULL
saline	NULL
and	NULL
injected	NULL
into	NULL
the	NULL
tail	NULL
veins	NULL
of	NULL
5-	NULL
to	NULL
8-week-old	NULL
FVB/N	NULL
mice	NULL
.	NULL

Transplantation	NULL
of	NULL
Bone	NULL
Marrow	NULL
.	NULL

Total	NULL
bone	NULL
marrow	NULL
isolated	NULL
from	NULL
the	NULL
tibiae	NULL
and	NULL
femurs	NULL
of	NULL
a	NULL
single	NULL
donor	NULL
was	NULL
divided	NULL
for	NULL
intravenous	NULL
injection	NULL
into	NULL
six	NULL
recipient	NULL
mice	NULL
.	NULL

Five-	NULL
to	NULL
12-week-old	NULL
FVB/N	NULL
mice	NULL
were	NULL
prepared	NULL
for	NULL
transplantation	NULL
by	NULL
cesium	NULL
irradiation	NULL
totaling	NULL
10.5	NULL
Gray	NULL
,	NULL
divided	NULL
in	NULL
two	NULL
doses	NULL
3-6	NULL
h	NULL
apart	NULL
.	NULL

ATRA	NULL
Treatment	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
after	NULL
transplantation	NULL
,	NULL
ATRA	NULL
was	NULL
administered	NULL
to	NULL
mice	NULL
via	NULL
one	NULL
of	NULL
two	NULL
routes	NULL
:	NULL
intraperitoneal	NULL
injection	NULL
of	NULL
100	NULL
wl	NULL
of	NULL
ATRA	NULL
(	NULL
Sigma	NULL
)	NULL
or	NULL
ethanol	NULL
vehicle	NULL
suspended	NULL
in	NULL
canola	NULL
or	NULL
peanut	NULL
oil	NULL
at	NULL
54	NULL
mg/kg	NULL
per	NULL
day	NULL
or	NULL
subcutaneous	NULL
implantation	NULL
of	NULL
a	NULL
21-day-release	NULL
pellet	NULL
containing	NULL
5	NULL
mg	NULL
ATRA	NULL
or	NULL
placebo	NULL
(	NULL
Innovative	NULL
Research	NULL
of	NULL
America	NULL
)	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
PMLRARa	NULL
in	NULL
Transgenic	NULL
Mice	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
PMLRARa	NULL
«	NULL
on	NULL
granulocyte	NULL
development	NULL
,	NULL
we	NULL
created	NULL
mice	NULL
that	NULL
expressed	NULL
a	NULL
human	NULL
PMLRARa	NULL
cDNA	NULL
(	NULL
10	NULL
)	NULL
from	NULL
the	NULL
AMRPS8	NULL
promoter	NULL
cassette	NULL
,	NULL
which	NULL
drives	NULL
transgene	NULL
expression	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Injections	NULL
into	NULL
FVB/N	NULL
embryos	NULL
yielded	NULL
nine	NULL
transgenic	NULL
lines	NULL
.	NULL

Levels	NULL
of	NULL
PMLRARa	NULL
transgene	NULL
expression	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
transgenic	NULL
mice	NULL
varied	NULL
from	NULL
virtually	NULL
undetectable	NULL
to	NULL
several-fold	NULL
higher	NULL
than	NULL
NB4	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
27	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
cells	NULL
in	NULL
the	NULL
transgenic	NULL
bone	NULL
marrow	NULL
expressed	NULL
PMLRARa	NULL
,	NULL
bone	NULL
marrow	NULL
cells	NULL
or	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
were	NULL
analyzed	NULL
by	NULL
immu-nofluorescence	NULL
using	NULL
antiserum	NULL
directed	NULL
against	NULL
human	NULL
Pml	NULL
.	NULL

PmlRara	NULL
was	NULL
distributed	NULL
in	NULL
a	NULL
speckled	NULL
nuclear	NULL
pattern	NULL
,	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Simultaneous	NULL
staining	NULL
with	NULL
DAPI	NULL
highlighted	NULL
the	NULL
distinctive	NULL
indented	NULL
,	NULL
horse-shoe-	NULL
or	NULL
doughnut-shaped	NULL
nuclei	NULL
characteristic	NULL
of	NULL
murine	NULL
granulocytes	NULL
(	NULL
Fig	NULL
.	NULL

le	NULL
)	NULL
,	NULL
verifying	NULL
that	NULL
the	NULL
transgene	NULL
was	NULL
expressed	NULL
in	NULL
the	NULL
granulocyte	NULL
lineage	NULL
.	NULL

In	NULL
lines	NULL
where	NULL
transgene	NULL
expression	NULL
was	NULL
undetectable	NULL
by	NULL
Western	NULL
blot	NULL
,	NULL
very	NULL
few	NULL
cells	NULL
were	NULL
stained	NULL
by	NULL
the	NULL
anti-Pml	NULL
antibody	NULL
;	NULL
in	NULL
lines	NULL
with	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
,	NULL
many	NULL
more	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
stained	NULL
(	NULL
data	NULL
not	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
€	NULL
_	NULL
€	NULL
<	NULL
\	NULL
z	NULL
g	NULL
o	NULL
ua	NULL
un	NULL
u	NULL
g	NULL
in	NULL
un	NULL
an	NULL
o	NULL
J	NULL
\	NULL
an	NULL
oce	NULL
a	NULL
\	NULL
a	NULL
~	NULL
a	NULL
Oo	NULL
A	NULL
Z	NULL
w	NULL
o	NULL
u	NULL
wo	NULL
Z2	NULL
~	NULL
w	NULL
o	NULL
az	NULL
.	NULL

w	NULL
PMLRARa	NULL
|	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

PMLRARa	NULL
expression	NULL
in	NULL
bone	NULL
marrow	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Western	NULL
blot	NULL
.	NULL

Total	NULL
cell	NULL
lysates	NULL
from	NULL
equal	NULL
numbers	NULL
of	NULL
unfrac-tionated	NULL
bone	NULL
marrow	NULL
cells	NULL
from	NULL
the	NULL
indicated	NULL
AMRPS-PMLRARa	NULL
transgenic	NULL
lines	NULL
or	NULL
control	NULL
cell	NULL
lines	NULL
were	NULL
loaded	NULL
into	NULL
each	NULL
lane	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
probed	NULL
with	NULL
antibodies	NULL
against	NULL
human	NULL
Rara	NULL
.	NULL

NB4	NULL
human	NULL
APL	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
express	NULL
PMLRARa	NULL
(	NULL
4	NULL
)	NULL
,	NULL
but	NULL
HL-60	NULL
human	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
do	NULL
not	NULL
(	NULL
28	NULL
)	NULL
.	NULL

FVB/N	NULL
samples	NULL
were	NULL
from	NULL
nontransgenic	NULL
mice	NULL
.	NULL

(	NULL
b-e	NULL
)	NULL
Immunofluorescence	NULL
.	NULL

Bone	NULL
marrow	NULL
cells	NULL
from	NULL
healthy	NULL
8-week-old	NULL
mice	NULL
were	NULL
cytospun	NULL
and	NULL
incubated	NULL
with	NULL
antiserum	NULL
specific	NULL
for	NULL
human	NULL
Pm	NULL
!	NULL

(	NULL
b	NULL
and	NULL
d	NULL
)	NULL
and	NULL
the	NULL
DNA-intercalating	NULL
dye	NULL
DAPI	NULL
(	NULL
c	NULL
and	NULL
e	NULL
)	NULL
.	NULL

(	NULL
b	NULL
and	NULL
c	NULL
)	NULL
Control	NULL
FVB/N	NULL
.	NULL

(	NULL
d	NULL
and	NULL
e	NULL
)	NULL
Transgenic	NULL
line	NULL
556	NULL
.	NULL

(	NULL
X250	NULL
.	NULL
)	NULL

shown	NULL
)	NULL
.	NULL

Altogether	NULL
,	NULL
we	NULL
detected	NULL
PmlRara	NULL
expression	NULL
in	NULL
granulocytes	NULL
from	NULL
eight	NULL
of	NULL
nine	NULL
transgenic	NULL
lines	NULL
.	NULL

Neutrophil	NULL
Maturation	NULL
Is	NULL
Impaired	NULL
in	NULL
PMLRARa	NULL
Transgenic	NULL
Mice	NULL
.	NULL

When	NULL
examined	NULL
microscopically	NULL
,	NULL
the	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
of	NULL
PMLRARa	NULL
«	NULL
transgenic	NULL
mice	NULL
resembled	NULL
the	NULL
controls	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
although	NULL
neutrophilic	NULL
cells	NULL
from	NULL
transgenic	NULL
mice	NULL
appeared	NULL
morphologically	NULL
normal	NULL
,	NULL
when	NULL
we	NULL
subjected	NULL
cells	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
or	NULL
bone	NULL
marrow	NULL
to	NULL
FACS	NULL
using	NULL
markers	NULL
for	NULL
myeloid	NULL
differentiation	NULL
,	NULL
subtle	NULL
aberrations	NULL
were	NULL
apparent	NULL
.	NULL

The	NULL
transgenic	NULL
samples	NULL
displayed	NULL
lower	NULL
levels	NULL
of	NULL
the	NULL
Gr-1	NULL
antigen	NULL
(	NULL
29	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
,	NULL
expression	NULL
of	NULL
which	NULL
increases	NULL
as	NULL
neutrophils	NULL
mature	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
transgenic	NULL
samples	NULL
also	NULL
had	NULL
lower	NULL
than	NULL
normal	NULL
levels	NULL
of	NULL
side-scatter	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
,	NULL
reflecting	NULL
a	NULL
low	NULL
cytoplasmic	NULL
granu-larity	NULL
,	NULL
which	NULL
is	NULL
typical	NULL
of	NULL
immature	NULL
granulocytes	NULL
.	NULL

Both	NULL
side-scatter	NULL
and	NULL
Gr-1	NULL
expression	NULL
were	NULL
inversely	NULL
related	NULL
to	NULL
the	NULL
level	NULL
of	NULL
transgene	NULL
expression	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
levels	NULL
of	NULL
CD11b	NULL
,	NULL
a	NULL
cell-surface	NULL
marker	NULL
that	NULL
also	NULL
increases	NULL
with	NULL
myeloid	NULL
differentiation	NULL
,	NULL
were	NULL
not	NULL
diminished	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
at	NULL
least	NULL
five	NULL
mice	NULL
each	NULL
from	NULL
three	NULL
transgenic	NULL
lines	NULL
(	NULL
553	NULL
,	NULL
556	NULL
,	NULL
and	NULL
565	NULL
)	NULL
,	NULL
and	NULL
the	NULL
aberrations	NULL
were	NULL
consistent	NULL
within	NULL
each	NULL
line	NULL
,	NULL
regardless	NULL
of	NULL
age	NULL
.	NULL

Granulocytic	NULL
cells	NULL
from	NULL
the	NULL
transgenic	NULL
mice	NULL
therefore	NULL
combined	NULL
features	NULL
of	NULL
both	NULL
immature	NULL
and	NULL
mature	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
reveal	NULL
that	NULL
PMLRARa	NULL
blocks	NULL
some	NULL
aspects	NULL
of	NULL
neutrophil	NULL
maturation	NULL
but	NULL
not	NULL
others	NULL
.	NULL

For	NULL
convenience	NULL
,	NULL
we	NULL
refer	NULL
to	NULL
this	NULL
condition	NULL
as	NULL
the	NULL
``	NULL
preleukemic	NULL
state	NULL
.	NULL
``	NULL

PMLRARa	NULL
Transgenic	NULL
Mice	NULL
Develop	NULL
APL	NULL
.	NULL

Twelve	NULL
PMLRARa	NULL
mice	NULL
from	NULL
five	NULL
independent	NULL
transgenic	NULL
lines	NULL
have	NULL
developed	NULL
APL	NULL
when	NULL
aged	NULL
3-9	NULL
months	NULL
(	NULL
median	NULL
,	NULL
174	NULL
days	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Assessment	NULL
of	NULL
lifetime	NULL
penetrance	NULL
of	NULL
the	NULL
leukemia	NULL
has	NULL
been	NULL
precluded	NULL
by	NULL
the	NULL
epidermal	NULL
papillomatosis	NULL
,	NULL
which	NULL
occurs	NULL
in	NULL
varying	NULL
degrees	NULL
in	NULL
all	NULL
the	NULL
mice	NULL
and	NULL
makes	NULL
it	NULL
difficult	NULL
to	NULL
maintain	NULL
mice	NULL
for	NULL
a	NULL
normal	NULL
life	NULL
span	NULL
(	NULL
to	NULL
be	NULL
reported	NULL
Medical	NULL
Sciences	NULL
:	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
2553	NULL
&	NULL
21	NULL
E-8	NULL
&	NULL
8-a	NULL
Aq	NULL
a*	NULL
#	NULL
01	NULL
o	NULL
-	NULL
o	NULL
o	NULL
}	NULL
Bo	NULL
WWho	NULL
00000000	NULL
foot-	NULL
FVB/N	NULL
Placebo	NULL
6	NULL
84	NULL
00000	NULL
lk	NULL
-	NULL
VW	NULL
0000000	NULL
|	NULL
--	NULL
FVB/N	NULL
ATRA	NULL
g	NULL
e	NULL
556	NULL
-	NULL
Placebo	NULL
556	NULL
-	NULL
ATRA	NULL
31	NULL
o	NULL
#	NULL
8	NULL
24	NULL
©	NULL
I	NULL
t	NULL
I.	NULL
T	NULL
*	NULL
©	NULL
10°	NULL
10	NULL
)	NULL
10°	NULL
10°	NULL
19	NULL
``	NULL
o	NULL
=	NULL
C	NULL
=	NULL
e	NULL
€	NULL
&	NULL
&	NULL
24	NULL
24	NULL
2	NULL
CE	NULL
5	NULL
._	NULL
%	NULL
L_	NULL
__	NULL
:	NULL
``	NULL
10°	NULL
10	NULL
)	NULL
10°	NULL
16°	NULL
io	NULL
0	NULL
Tot	NULL
10	NULL
)	NULL
102	NULL
10°	NULL
10°	NULL
art	NULL
an	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

FACS	NULL
analysis	NULL
of	NULL
bone	NULL
marrow	NULL
.	NULL

Bone	NULL
marrow	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
Gr-1	NULL
and	NULL
Mac-1	NULL
(	NULL
murine	NULL
Cd11b	NULL
)	NULL
,	NULL
markers	NULL
for	NULL
differentiation	NULL
of	NULL
murine	NULL
myeloid	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
and	NULL
b	NULL
)	NULL
Placebo	NULL
or	NULL
5	NULL
mg	NULL
ATRA	NULL
pellets	NULL
were	NULL
implanted	NULL
into	NULL
3-week-old	NULL
FVB/N	NULL
or	NULL
line	NULL
556	NULL
mice	NULL
;	NULL
marrow	NULL
was	NULL
analyzed	NULL
after	NULL
21	NULL
days	NULL
.	NULL

Each	NULL
curve	NULL
combines	NULL
data	NULL
from	NULL
two	NULL
mice	NULL
.	NULL

FVB/N-placebo	NULL
,	NULL
dotted	NULL
line	NULL
;	NULL
line	NULL
556-placebo	NULL
,	NULL
thin	NULL
line	NULL
;	NULL
FVB/N-ATRA	NULL
,	NULL
dashed	NULL
line	NULL
;	NULL
line	NULL
556-ATRA	NULL
,	NULL
thick	NULL
line	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Gr-1	NULL
antigen	NULL
expression	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Side-scatter	NULL
profile	NULL
of	NULL
Gr-1-positive	NULL
cells	NULL
from	NULL
samples	NULL
in	NULL
2	NULL
.	NULL

(	NULL
c-e	NULL
)	NULL
Murine	NULL
APL	NULL
responds	NULL
to	NULL
ATRA	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Age-matched	NULL
FVB/N	NULL
control	NULL
.	NULL

(	NULL
d	NULL
and	NULL
e	NULL
)	NULL
Samples	NULL
from	NULL
second	NULL
passage	NULL
by	NULL
transplantation	NULL
of	NULL
leukemia	NULL
935	NULL
(	NULL
line	NULL
569	NULL
)	NULL
.	NULL

On	NULL
days	NULL
14-21	NULL
after	NULL
transplantation	NULL
,	NULL
mice	NULL
were	NULL
given	NULL
placebo	NULL
(	NULL
d	NULL
)	NULL
or	NULL
1.35	NULL
mg	NULL
ATRA	NULL
(	NULL
e	NULL
)	NULL
by	NULL
intraperitoneal	NULL
injection	NULL
of	NULL
oil	NULL
suspension	NULL
.	NULL

Cells	NULL
were	NULL
isolated	NULL
on	NULL
day	NULL
28	NULL
after	NULL
transplantation	NULL
.	NULL

elsewhere	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
penetrance	NULL
of	NULL
the	NULL
leukemia	NULL
may	NULL
correlate	NULL
with	NULL
overall	NULL
levels	NULL
of	NULL
transgene	NULL
expression	NULL
:	NULL
although	NULL
leukemias	NULL
have	NULL
been	NULL
seen	NULL
in	NULL
lines	NULL
with	NULL
relatively	NULL
low	NULL
levels	NULL
of	NULL
PMLRARa	NULL
expression	NULL
,	NULL
the	NULL
disease	NULL
has	NULL
been	NULL
more	NULL
frequent	NULL
in	NULL
mice	NULL
from	NULL
the	NULL
high-expressing	NULL
556	NULL
line	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
leukemic	NULL
mice	NULL
were	NULL
abnormally	NULL
susceptible	NULL
to	NULL
bleeding	NULL
after	NULL
injections	NULL
,	NULL
and	NULL
a	NULL
few	NULL
mice	NULL
hemorrhaged	NULL
spontaneously	NULL
.	NULL

In	NULL
some	NULL
mice	NULL
,	NULL
fibrin	NULL
thrombi	NULL
were	NULL
present	NULL
in	NULL
pulmonary	NULL
blood	NULL
vessels	NULL
but	NULL
not	NULL
in	NULL
other	NULL
organs	NULL
.	NULL

Peripheral	NULL
blood	NULL
counts	NULL
were	NULL
notable	NULL
for	NULL
anemia	NULL
and	NULL
thrombocytopenia	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
increased	NULL
numbers	NULL
of	NULL
white	NULL
blood	NULL
cells	NULL
(	NULL
0.8-7.9	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
leukemias	NULL
vs.	NULL
1.1-8.3	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
controls	NULL
)	NULL
.	NULL

A	NULL
bleeding	NULL
diathesis	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
normal	NULL
or	NULL
even	NULL
low	NULL
white	NULL
counts	NULL
is	NULL
typical	NULL
of	NULL
human	NULL
APL	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
pathology	NULL
of	NULL
the	NULL
leukemia	NULL
was	NULL
consistent	NULL
among	NULL
the	NULL
various	NULL
transgenic	NULL
lines	NULL
.	NULL

Pale	NULL
bone	NULL
marrow	NULL
was	NULL
accompanied	NULL
by	NULL
lymphadenopathy	NULL
and	NULL
hepatosplenomegaly	NULL
.	NULL

Microscopically	NULL
,	NULL
the	NULL
mixed	NULL
hematopoiesis	NULL
of	NULL
normal	NULL
bone	NULL
marrow	NULL
was	NULL
Table	NULL
1	NULL
.	NULL

Transgene	NULL
expression	NULL
and	NULL
leukemia	NULL
incidence	NULL
Age	NULL
at	NULL
Mice	NULL
PmlRara	NULL
APL	NULL
diagnosis	NULL
,	NULL
reaching	NULL
age	NULL
Line	NULL
expression	NULL
*	NULL
cases	NULL
days	NULL
174	NULL
dayst	NULL
506	NULL
++	NULL
2	NULL
174	NULL
,	NULL
195	NULL
45	NULL
553	NULL
+	NULL
3	NULL
78	NULL
,	NULL
174	NULL
,	NULL
265	NULL
79	NULL
556	NULL
+++	NULL
5	NULL
92	NULL
,	NULL
143	NULL
,	NULL
149	NULL
,	NULL
16	NULL
176	NULL
,	NULL
203	NULL
565	NULL
++	NULL
0	NULL
31	NULL
569	NULL
+	NULL
1	NULL
155	NULL
12	NULL
608	NULL
+	NULL
1	NULL
247	NULL
34	NULL
*Relative	NULL
levels	NULL
based	NULL
on	NULL
visual	NULL
comparison	NULL
of	NULL
western	NULL
blot	NULL
and	NULL
immunofluorescence	NULL
.	NULL

*Includes	NULL
living	NULL
mice	NULL
and	NULL
those	NULL
aged	NULL
at	NULL
least	NULL
174	NULL
days	NULL
at	NULL
death	NULL
(	NULL
median	NULL
age	NULL
at	NULL
diagnosis	NULL
of	NULL
APL	NULL
)	NULL
.	NULL

completely	NULL
replaced	NULL
by	NULL
leukemic	NULL
cells	NULL
,	NULL
splenic	NULL
and	NULL
lymphatic	NULL
architecture	NULL
was	NULL
effaced	NULL
,	NULL
and	NULL
leukemia	NULL
extended	NULL
throughout	NULL
the	NULL
hepatic	NULL
parenchyma	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
extensive	NULL
invasion	NULL
of	NULL
the	NULL
kidneys	NULL
,	NULL
reproductive	NULL
organs	NULL
,	NULL
or	NULL
the	NULL
meninges	NULL
was	NULL
also	NULL
observed	NULL
.	NULL

Morphologically	NULL
,	NULL
the	NULL
leukemic	NULL
cells	NULL
were	NULL
promyelocytes	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
)	NULL
:	NULL
they	NULL
were	NULL
large	NULL
,	NULL
had	NULL
oval	NULL
to	NULL
indented	NULL
nuclei	NULL
and	NULL
abundant	NULL
basophilic	NULL
cytoplasm	NULL
with	NULL
many	NULL
primary	NULL
granules	NULL
.	NULL

Mitotic	NULL
figures	NULL
and	NULL
dysplastic	NULL
nuclei	NULL
were	NULL
present	NULL
.	NULL

Although	NULL
we	NULL
have	NULL
not	NULL
observed	NULL
Auer	NULL
rods	NULL
or	NULL
faggot	NULL
cells	NULL
in	NULL
these	NULL
leukemias	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
characteristic	NULL
of	NULL
human	NULL
APL	NULL
(	NULL
31	NULL
)	NULL
,	NULL
we	NULL
note	NULL
that	NULL
maturing	NULL
human	NULL
and	NULL
murine	NULL
granulocytes	NULL
are	NULL
morphologically	NULL
distinct	NULL
,	NULL
and	NULL
morphological	NULL
variations	NULL
might	NULL
be	NULL
expected	NULL
between	NULL
human	NULL
and	NULL
murine	NULL
leukemias	NULL
arising	NULL
from	NULL
this	NULL
lineage	NULL
.	NULL

Like	NULL
human	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
,	NULL
the	NULL
murine	NULL
leukemia	NULL
cells	NULL
stained	NULL
strongly	NULL
with	NULL
Sudan	NULL
Black	NULL
B	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
marks	NULL
the	NULL
myeloperoxidase	NULL
found	NULL
in	NULL
the	NULL
primary	NULL
granules	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
promyelocyte/	NULL
granulocyte	NULL
lineage	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
expressed	NULL
low	NULL
levels	NULL
of	NULL
Gr-1	NULL
and	NULL
Mac-1	NULL
antigens	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
;	NULL
low	NULL
expression	NULL
of	NULL
CD11b	NULL
,	NULL
the	NULL
surface	NULL
marker	NULL
detected	NULL
by	NULL
the	NULL
Mac-1	NULL
antibody	NULL
,	NULL
is	NULL
characteristic	NULL
of	NULL
APL	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
.	NULL

In	NULL
7-day	NULL
methylcellulose	NULL
culture	NULL
,	NULL
leukemic	NULL
bone	NULL
marrow	NULL
gave	NULL
rise	NULL
to	NULL
abundant	NULL
compact	NULL
colo-nies	NULL
.	NULL

Cytospins	NULL
of	NULL
cells	NULL
isolated	NULL
from	NULL
these	NULL
cultures	NULL
principally	NULL
contained	NULL
promyelocytes	NULL
(	NULL
Fig	NULL
.	NULL

3¢c	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
transgenic	NULL
mice	NULL
had	NULL
developed	NULL
APL	NULL
.	NULL

Murine	NULL
APL	NULL
and	NULL
the	NULL
Preleukemic	NULL
State	NULL
Are	NULL
Transplant-able	NULL
.	NULL

To	NULL
further	NULL
verify	NULL
the	NULL
malignant	NULL
character	NULL
of	NULL
the	NULL
myeloid	NULL
leukemia	NULL
,	NULL
we	NULL
transplanted	NULL
leukemic	NULL
cells	NULL
into	NULL
unirradiated	NULL
FVB/N	NULL
mice	NULL
.	NULL

We	NULL
intravenously	NULL
injected	NULL
cells	NULL
isolated	NULL
from	NULL
the	NULL
bone	NULL
marrow	NULL
or	NULL
spleen	NULL
of	NULL
leukemic	NULL
donors	NULL
.	NULL

To	NULL
date	NULL
,	NULL
five	NULL
leukemias	NULL
have	NULL
been	NULL
tested	NULL
with	NULL
similar	NULL
results	NULL
:	NULL
3-5	NULL
weeks	NULL
after	NULL
transplantation	NULL
,	NULL
the	NULL
recipient	NULL
mice	NULL
developed	NULL
leukemia	NULL
.	NULL

Clinical	NULL
and	NULL
pathological	NULL
features	NULL
resembled	NULL
the	NULL
disease	NULL
in	NULL
the	NULL
donors	NULL
.	NULL

Morphologically	NULL
and	NULL
by	NULL
FACS	NULL
analysis	NULL
,	NULL
the	NULL
leukemic	NULL
2554	NULL
Medical	NULL
Sciences	NULL
:	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

FiG	NULL
.	NULL

3	NULL
.	NULL

Murine	NULL
APL	NULL
.	NULL

(	NULL
@	NULL
and	NULL
b	NULL
)	NULL
Bone	NULL
marrow	NULL
isolates	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Control	NULL
FVB/N	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Leukemia	NULL
(	NULL
mouse	NULL
1333	NULL
,	NULL
line	NULL
556	NULL
)	NULL
.	NULL

(	NULL
c	NULL
and	NULL
d	NULL
)	NULL
Cytospins	NULL
of	NULL
7-day	NULL
methylcellulose	NULL
cultures	NULL
from	NULL
passage	NULL
1	NULL
of	NULL
leukemia	NULL
877	NULL
(	NULL
line	NULL
553	NULL
)	NULL
cultured	NULL
without	NULL
(	NULL
c	NULL
)	NULL
or	NULL
with	NULL
(	NULL
d	NULL
)	NULL
1	NULL
uM	NULL
ATRA	NULL
.	NULL

(	NULL
e	NULL
and	NULL
f	NULL
)	NULL
Bone	NULL
marrow	NULL
isolates	NULL
from	NULL
third	NULL
passage	NULL
of	NULL
leukemia	NULL
877	NULL
.	NULL

On	NULL
day	NULL
11	NULL
after	NULL
transplantation	NULL
,	NULL
pellets	NULL
containing	NULL
placebo	NULL
(	NULL
e	NULL
)	NULL
or	NULL
5	NULL
mg	NULL
ATRA	NULL
(	NULL
f	NULL
)	NULL
were	NULL
implanted	NULL
.	NULL

Samples	NULL
were	NULL
prepared	NULL
on	NULL
day	NULL
16	NULL
after	NULL
transplantation	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
Wright	NULL
's	NULL
Giemsa	NULL
with	NULL
Azure	NULL
B	NULL
.	NULL

(	NULL
X250	NULL
.	NULL
)	NULL

cells	NULL
were	NULL
identical	NULL
to	NULL
the	NULL
donor	NULL
cells	NULL
When	NULL
analyzed	NULL
by	NULL
immunofluorescence	NULL
,	NULL
samples	NULL
from	NULL
the	NULL
transplant	NULL
recipients	NULL
stained	NULL
intensely	NULL
with	NULL
anti-Pml	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
recipient	NULL
mice	NULL
did	NULL
not	NULL
carry	NULL
the	NULL
transgene	NULL
,	NULL
this	NULL
verified	NULL
that	NULL
the	NULL
leukemic	NULL
cells	NULL
themselves	NULL
expressed	NULL
PMLRARa	NULL
.	NULL

We	NULL
were	NULL
also	NULL
able	NULL
to	NULL
transplant	NULL
the	NULL
preleukemic	NULL
state	NULL
by	NULL
injecting	NULL
bone	NULL
marrow	NULL
from	NULL
young	NULL
,	NULL
healthy	NULL
transgenic	NULL
mice	NULL
into	NULL
lethally	NULL
irradiated	NULL
FVB/N	NULL
mice	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
6	NULL
of	NULL
45	NULL
recipient	NULL
mice	NULL
and	NULL
all	NULL
displayed	NULL
marrow	NULL
and	NULL
blood	NULL
FACS	NULL
profiles	NULL
characteristic	NULL
of	NULL
the	NULL
transgenic	NULL
line	NULL
of	NULL
the	NULL
donor	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
have	NULL
seen	NULL
9	NULL
cases	NULL
of	NULL
APL	NULL
in	NULL
the	NULL
recipients	NULL
to	NULL
date	NULL
.	NULL

These	NULL
results	NULL
demonstrated	NULL
that	NULL
the	NULL
observed	NULL
hemato-logical	NULL
abnormalities	NULL
were	NULL
not	NULL
a	NULL
reaction	NULL
to	NULL
the	NULL
papillomas	NULL
,	NULL
and	NULL
provide	NULL
the	NULL
opportunity	NULL
to	NULL
define	NULL
the	NULL
incidence	NULL
of	NULL
leukemia	NULL
and	NULL
study	NULL
tumor	NULL
progression	NULL
in	NULL
a	NULL
setting	NULL
free	NULL
of	NULL
the	NULL
epidermal	NULL
disease	NULL
.	NULL

Murine	NULL
APL	NULL
Differentiates	NULL
in	NULL
Response	NULL
to	NULL
ATRA	NULL
in	NULL
Vitro	NULL
and	NULL
in	NULL
Vivo	NULL
.	NULL

We	NULL
wanted	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
murine	NULL
leukemia	NULL
responded	NULL
to	NULL
ATRA	NULL
like	NULL
the	NULL
human	NULL
leukemia	NULL
;	NULL
the	NULL
ability	NULL
to	NULL
passage	NULL
the	NULL
leukemias	NULL
enabled	NULL
us	NULL
to	NULL
generate	NULL
additional	NULL
material	NULL
for	NULL
these	NULL
studies	NULL
.	NULL

When	NULL
cultured	NULL
for	NULL
7	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ATRA	NULL
,	NULL
the	NULL
compact	NULL
colonies	NULL
seen	NULL
in	NULL
untreated	NULL
cultures	NULL
were	NULL
almost	NULL
entirely	NULL
replaced	NULL
by	NULL
colonies	NULL
with	NULL
an	NULL
open	NULL
,	NULL
spreading	NULL
appearance	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
ATRA	NULL
was	NULL
inducing	NULL
differentiation	NULL
,	NULL
since	NULL
mature	NULL
neutrophils	NULL
are	NULL
mobile	NULL
.	NULL

Cytospins	NULL
of	NULL
treated	NULL
cultures	NULL
chiefly	NULL
consisted	NULL
of	NULL
mature	NULL
neutrophils	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrated	NULL
that	NULL
the	NULL
leukemic	NULL
cells	NULL
could	NULL
be	NULL
differentiated	NULL
by	NULL
ATRA	NULL
treatment	NULL
.	NULL

Next	NULL
we	NULL
examined	NULL
the	NULL
ATRA	NULL
response	NULL
in	NULL
mice	NULL
.	NULL

We	NULL
first	NULL
used	NULL
a	NULL
suspension	NULL
of	NULL
ATRA	NULL
in	NULL
oil	NULL
for	NULL
intraperitoneal	NULL
injection	NULL
.	NULL

The	NULL
dose	NULL
was	NULL
calculated	NULL
to	NULL
approximate	NULL
the	NULL
blood	NULL
levels	NULL
achieved	NULL
in	NULL
human	NULL
patients	NULL
,	NULL
with	NULL
corrections	NULL
for	NULL
different	NULL
route	NULL
of	NULL
administration	NULL
and	NULL
more	NULL
rapid	NULL
murine	NULL
metabolism	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

ATRA	NULL
and	NULL
placebo	NULL
injections	NULL
were	NULL
begun	NULL
in	NULL
four	NULL
and	NULL
two	NULL
animals	NULL
,	NULL
respectively	NULL
,	NULL
on	NULL
day	NULL
15	NULL
after	NULL
transplantation	NULL
,	NULL
when	NULL
promyelocytes	NULL
were	NULL
present	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
;	NULL
on	NULL
day	NULL
21	NULL
after	NULL
transplantation	NULL
,	NULL
injections	NULL
were	NULL
stopped	NULL
and	NULL
one	NULL
mouse	NULL
killed	NULL
due	NULL
to	NULL
onset	NULL
of	NULL
vitamin	NULL
A	NULL
toxicity	NULL
.	NULL

On	NULL
day	NULL
28	NULL
,	NULL
a	NULL
moribund	NULL
placebo-treated	NULL
mouse	NULL
and	NULL
a	NULL
healthy	NULL
ATRA-treated	NULL
mouse	NULL
were	NULL
killed	NULL
and	NULL
their	NULL
bone	NULL
marrows	NULL
were	NULL
analyzed	NULL
by	NULL
FACS	NULL
.	NULL

Comparison	NULL
of	NULL
cells	NULL
stained	NULL
with	NULL
Gr-1	NULL
and	NULL
Mac-1	NULL
antibodies	NULL
showed	NULL
two	NULL
main	NULL
clusters	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
FVB/N	NULL
control	NULL
marrow	NULL
(	NULL
Fig	NULL
.	NULL

2¢c	NULL
)	NULL
:	NULL
nonmyeloid	NULL
cells	NULL
,	NULL
negative	NULL
for	NULL
both	NULL
markers	NULL
,	NULL
and	NULL
maturing	NULL
neutrophils	NULL
,	NULL
strongly	NULL
positive	NULL
for	NULL
both	NULL
markers	NULL
.	NULL

In	NULL
the	NULL
placebo-treated	NULL
mouse	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
the	NULL
bulk	NULL
of	NULL
the	NULL
marrow	NULL
was	NULL
composed	NULL
of	NULL
leukemic	NULL
cells	NULL
expressing	NULL
low	NULL
levels	NULL
of	NULL
Gr-1	NULL
and	NULL
Mac-1	NULL
.	NULL

ATRA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

22	NULL
)	NULL
restored	NULL
a	NULL
near-normal	NULL
distribution	NULL
of	NULL
Gr-1	NULL
and	NULL
Mac-1	NULL
staining	NULL
.	NULL

The	NULL
FACS	NULL
changes	NULL
were	NULL
accompanied	NULL
by	NULL
the	NULL
appearance	NULL
of	NULL
mature	NULL
neutrophils	NULL
in	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
and	NULL
by	NULL
lessened	NULL
hepatosplenomegaly	NULL
and	NULL
lymphadenopathy	NULL
in	NULL
treated	NULL
mice	NULL
.	NULL

The	NULL
two	NULL
remaining	NULL
ATRA-treated	NULL
mice	NULL
were	NULL
monitored	NULL
to	NULL
examine	NULL
their	NULL
long-term	NULL
response	NULL
to	NULL
therapy	NULL
.	NULL

They	NULL
continued	NULL
in	NULL
apparent	NULL
remission	NULL
until	NULL
one	NULL
relapsed	NULL
47	NULL
days	NULL
after	NULL
the	NULL
end	NULL
of	NULL
treatment	NULL
(	NULL
68	NULL
days	NULL
after	NULL
transplantation	NULL
)	NULL
,	NULL
while	NULL
the	NULL
other	NULL
remains	NULL
in	NULL
good	NULL
health	NULL
7	NULL
months	NULL
after	NULL
transplantation	NULL
.	NULL

Subsequently	NULL
,	NULL
we	NULL
have	NULL
subcutaneously	NULL
implanted	NULL
21-day	NULL
release	NULL
pellets	NULL
(	NULL
containing	NULL
either	NULL
5	NULL
mg	NULL
ATRA	NULL
or	NULL
placebo	NULL
)	NULL
10-20	NULL
days	NULL
after	NULL
transplantation	NULL
.	NULL

These	NULL
obviated	NULL
the	NULL
need	NULL
for	NULL
daily	NULL
injections	NULL
and	NULL
did	NULL
not	NULL
lead	NULL
to	NULL
overdose	NULL
.	NULL

In	NULL
trials	NULL
involving	NULL
6-12	NULL
animals	NULL
each	NULL
,	NULL
we	NULL
have	NULL
tested	NULL
recipients	NULL
of	NULL
transplants	NULL
from	NULL
4	NULL
cases	NULL
of	NULL
leukemia	NULL
,	NULL
and	NULL
have	NULL
observed	NULL
consistent	NULL
responses	NULL
to	NULL
ATRA	NULL
pellets	NULL
.	NULL

Within	NULL
3-5	NULL
days	NULL
of	NULL
initiating	NULL
treatment	NULL
,	NULL
increasing	NULL
numbers	NULL
of	NULL
neutrophils	NULL
appeared	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
(	NULL
Fig	NULL
.	NULL

3f	NULL
)	NULL
.	NULL

The	NULL
mice	NULL
treated	NULL
with	NULL
the	NULL
ATRA	NULL
pellets	NULL
generally	NULL
did	NULL
not	NULL
survive	NULL
much	NULL
longer	NULL
than	NULL
those	NULL
treated	NULL
with	NULL
placebos	NULL
,	NULL
but	NULL
we	NULL
suspect	NULL
that	NULL
their	NULL
deaths	NULL
were	NULL
related	NULL
to	NULL
the	NULL
pulse	NULL
of	NULL
differentiating	NULL
neutrophils	NULL
rather	NULL
than	NULL
to	NULL
the	NULL
leukemia	NULL
itself	NULL
,	NULL
since	NULL
maturing	NULL
neutrophils	NULL
were	NULL
the	NULL
predominant	NULL
cell	NULL
type	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrows	NULL
of	NULL
treated	NULL
mice	NULL
.	NULL

These	NULL
adverse	NULL
results	NULL
of	NULL
ATRA	NULL
treatment	NULL
may	NULL
represent	NULL
a	NULL
murine	NULL
version	NULL
of	NULL
the	NULL
``	NULL
retinoic	NULL
acid	NULL
syndrome	NULL
,	NULL
``	NULL
which	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
related	NULL
to	NULL
the	NULL
rapid	NULL
expansion	NULL
of	NULL
the	NULL
neutrophil	NULL
population	NULL
induced	NULL
by	NULL
differentiation	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
treating	NULL
the	NULL
leukemia	NULL
with	NULL
ATRA	NULL
,	NULL
we	NULL
implanted	NULL
ATRA	NULL
or	NULL
placebo	NULL
pellets	NULL
into	NULL
transgenic	NULL
mice	NULL
that	NULL
did	NULL
not	NULL
have	NULL
leukemia	NULL
.	NULL

The	NULL
distribution	NULL
of	NULL
Gr-1	NULL
expression	NULL
and	NULL
side-scatter	NULL
was	NULL
shifted	NULL
toward	NULL
normal	NULL
levels	NULL
in	NULL
five	NULL
of	NULL
five	NULL
ATRA-treated	NULL
transgenic	NULL
mice	NULL
,	NULL
while	NULL
control	NULL
FVB/N	NULL
were	NULL
unaffected	NULL
by	NULL
the	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
a	NULL
and	NULL
b	NULL
)	NULL
.	NULL

It	NULL
thus	NULL
appears	NULL
that	NULL
the	NULL
drug	NULL
overcomes	NULL
the	NULL
preneoplastic	NULL
changes	NULL
as	NULL
well	NULL
as	NULL
the	NULL
acute	NULL
leukemia	NULL
,	NULL
reinforcing	NULL
the	NULL
hypothesis	NULL
that	NULL
ATRA	NULL
can	NULL
correct	NULL
abnormalities	NULL
elicited	NULL
by	NULL
expression	NULL
of	NULL
PMLRARa	NULL
in	NULL
neutrophils	NULL
.	NULL

DISCUSSION	NULL
PMLRARa	NULL
Impairs	NULL
Neutrophil	NULL
Differentiation	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
human	NULL
PMLRARa	NULL
cDNA	NULL
in	NULL
murine	NULL
granulocyte	NULL
precursor	NULL
cells	NULL
alters	NULL
their	NULL
differentiation	NULL
and	NULL
initiates	NULL
the	NULL
development	NULL
of	NULL
APL	NULL
.	NULL

Some	NULL
aspects	NULL
of	NULL
neutrophilic	NULL
differentiation	NULL
were	NULL
sensitive	NULL
to	NULL
inhibition	NULL
by	NULL
PmlRara	NULL
,	NULL
others	NULL
were	NULL
not	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
myeloid	NULL
differentiation	NULL
marker	NULL
CD11b	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
PmlRara	NULL
,	NULL
in	NULL
accord	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
in	NULL
which	NULL
PMLRARa	NULL
was	NULL
expressed	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Our	NULL
in	NULL
vivo	NULL
results	NULL
confirm	NULL
the	NULL
hypothesis	NULL
that	NULL
expression	NULL
of	NULL
PMLRARa	NULL
in	NULL
otherwise	NULL
normal	NULL
granulocytic	NULL
cells	NULL
impairs	NULL
their	NULL
maturation	NULL
,	NULL
and	NULL
define	NULL
a	NULL
preleukemic	NULL
state	NULL
elicited	NULL
by	NULL
PMLRARa	NULL
.	NULL

It	NULL
could	NULL
be	NULL
argued	NULL
that	NULL
the	NULL
severe	NULL
epidermal	NULL
papillomatosis	NULL
seen	NULL
in	NULL
the	NULL
transgenic	NULL
mice	NULL
might	NULL
have	NULL
secondary	NULL
effects	NULL
that	NULL
could	NULL
account	NULL
for	NULL
a	NULL
disturbance	NULL
in	NULL
granulopoiesis	NULL
.	NULL

We	NULL
do	NULL
not	NULL
Medical	NULL
Sciences	NULL
:	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

believe	NULL
that	NULL
this	NULL
is	NULL
the	NULL
case	NULL
:	NULL
we	NULL
have	NULL
seen	NULL
consistent	NULL
FACS	NULL
abnormalities	NULL
in	NULL
transgenic	NULL
mice	NULL
as	NULL
young	NULL
as	NULL
3	NULL
weeks	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
visible	NULL
skin	NULL
lesions	NULL
,	NULL
and	NULL
preleukemic	NULL
marrow	NULL
transplanted	NULL
into	NULL
nontransgenic	NULL
mice	NULL
retains	NULL
its	NULL
characteristic	NULL
phenotypic	NULL
abnormalities	NULL
and	NULL
propensity	NULL
to	NULL
develop	NULL
APL	NULL
PMLRARa	NULL
Initiates	NULL
APL	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
preneoplastic	NULL
changes	NULL
in	NULL
granulopoiesis	NULL
,	NULL
hMRPS-PMLRARa	NULL
transgenic	NULL
mice	NULL
develop	NULL
acute	NULL
leukemia	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
expression	NULL
of	NULL
PMLRARa	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
cause	NULL
leukemia	NULL
because	NULL
the	NULL
leukemic	NULL
phenotype	NULL
combines	NULL
incomplete	NULL
penetrance	NULL
with	NULL
delayed	NULL
onset	NULL
.	NULL

While	NULL
the	NULL
epidermal	NULL
papillomatosis	NULL
has	NULL
limited	NULL
median	NULL
survival	NULL
in	NULL
the	NULL
most	NULL
severely	NULL
afflicted	NULL
transgenic	NULL
lines	NULL
to	NULL
3-5	NULL
months	NULL
,	NULL
we	NULL
suspect	NULL
the	NULL
incidence	NULL
of	NULL
leukemia	NULL
in	NULL
most	NULL
of	NULL
the	NULL
transgenic	NULL
lines	NULL
may	NULL
be	NULL
only	NULL
a	NULL
few	NULL
percent	NULL
over	NULL
the	NULL
normal	NULL
life	NULL
span	NULL
of	NULL
the	NULL
mice	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
results	NULL
with	NULL
a	NULL
small	NULL
number	NULL
of	NULL
bone	NULL
marrow	NULL
transplants	NULL
suggest	NULL
an	NULL
incidence	NULL
approaching	NULL
30	NULL
%	NULL
at	NULL
1	NULL
year	NULL
in	NULL
the	NULL
high	NULL
expressing	NULL
line	NULL
556	NULL
.	NULL

Initial	NULL
results	NULL
indicate	NULL
that	NULL
crossing	NULL
transgenic	NULL
lines	NULL
556	NULL
and	NULL
565	NULL
yields	NULL
higher	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
and	NULL
a	NULL
greater	NULL
incidence	NULL
of	NULL
leukemia	NULL
,	NULL
without	NULL
changing	NULL
the	NULL
latency	NULL
.	NULL

The	NULL
3-	NULL
to	NULL
9-month	NULL
latency	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
taken	NULL
together	NULL
with	NULL
the	NULL
low	NULL
penetrance	NULL
of	NULL
leukemia	NULL
,	NULL
suggests	NULL
that	NULL
leukemogenesis	NULL
by	NULL
PMLRARa	NULL
requires	NULL
additional	NULL
genetic	NULL
changes	NULL
.	NULL

Expression	NULL
of	NULL
PMLRARa	NULL
may	NULL
facilitate	NULL
the	NULL
acquisition	NULL
of	NULL
additional	NULL
genetic	NULL
changes	NULL
.	NULL

Although	NULL
the	NULL
transgenic	NULL
mice	NULL
did	NULL
not	NULL
show	NULL
a	NULL
clear	NULL
expansion	NULL
of	NULL
the	NULL
myeloid	NULL
compartment	NULL
prior	NULL
to	NULL
the	NULL
development	NULL
of	NULL
APL	NULL
,	NULL
increased	NULL
proliferation	NULL
might	NULL
be	NULL
balanced	NULL
by	NULL
increased	NULL
destruction	NULL
,	NULL
the	NULL
balance	NULL
between	NULL
differentiation	NULL
and	NULL
self-renewal	NULL
might	NULL
be	NULL
altered	NULL
,	NULL
or	NULL
genomic	NULL
instability	NULL
might	NULL
be	NULL
increased	NULL
.	NULL

These	NULL
mechanisms	NULL
could	NULL
enhance	NULL
accumulation	NULL
of	NULL
mutations	NULL
that	NULL
further	NULL
block	NULL
differentiation	NULL
,	NULL
promote	NULL
proliferation	NULL
,	NULL
or	NULL
decrease	NULL
apoptosis	NULL
of	NULL
the	NULL
promyelocytic	NULL
cells	NULL
.	NULL

In	NULL
collaboration	NULL
with	NULL
PmlRara	NULL
,	NULL
these	NULL
genetic	NULL
changes	NULL
could	NULL
then	NULL
release	NULL
promyelocytes	NULL
from	NULL
normal	NULL
growth	NULL
constraints	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
uncontrolled	NULL
proliferation	NULL
of	NULL
malignancy	NULL
.	NULL

The	NULL
Murine	NULL
Leukemia	NULL
Is	NULL
an	NULL
Accurate	NULL
Model	NULL
for	NULL
Human	NULL
APL	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
the	NULL
murine	NULL
leukemia	NULL
described	NULL
here	NULL
is	NULL
a	NULL
true	NULL
analog	NULL
of	NULL
the	NULL
human	NULL
disease	NULL
.	NULL

APL	NULL
in	NULL
both	NULL
species	NULL
shares	NULL
the	NULL
promyelocytic	NULL
character	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
and	NULL
differentiation	NULL
in	NULL
response	NULL
to	NULL
ATRA	NULL
(	NULL
with	NULL
both	NULL
therapeutic	NULL
and	NULL
adverse	NULL
effects	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
further	NULL
authenticate	NULL
the	NULL
role	NULL
of	NULL
PMLRARa	NULL
in	NULL
the	NULL
specific	NULL
pathogenesis	NULL
of	NULL
APL	NULL
.	NULL

Also	NULL
similar	NULL
to	NULL
human	NULL
APL	NULL
is	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
bleeding	NULL
tendency	NULL
in	NULL
leukemic	NULL
mice	NULL
.	NULL

The	NULL
etiology	NULL
of	NULL
bleeding	NULL
in	NULL
the	NULL
mice	NULL
remains	NULL
uncertain	NULL
,	NULL
however	NULL
,	NULL
since	NULL
we	NULL
have	NULL
not	NULL
observed	NULL
disseminated	NULL
intravascular	NULL
thrombi	NULL
.	NULL

Other	NULL
investigators	NULL
have	NULL
prepared	NULL
mice	NULL
in	NULL
which	NULL
transgenic	NULL
PMLRARa	NULL
is	NULL
expressed	NULL
by	NULL
transcriptional	NULL
controls	NULL
for	NULL
either	NULL
the	NULL
CD11b	NULL
gene	NULL
(	NULL
37	NULL
)	NULL
or	NULL
the	NULL
human	NULL
cathepsin	NULL
G	NULL
gene	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
CD11b	NULL
mice	NULL
failed	NULL
to	NULL
develop	NULL
either	NULL
preleukemia	NULL
or	NULL
leukemia	NULL
.	NULL

Their	NULL
only	NULL
apparent	NULL
abnormality	NULL
was	NULL
an	NULL
increased	NULL
sensitivity	NULL
to	NULL
doses	NULL
of	NULL
irradiation	NULL
that	NULL
are	NULL
normally	NULL
sublethal	NULL
,	NULL
succumbing	NULL
to	NULL
infections	NULL
because	NULL
of	NULL
protracted	NULL
bone	NULL
marrow	NULL
suppression	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
not	NULL
immediately	NULL
apparent	NULL
that	NULL
these	NULL
mice	NULL
offer	NULL
any	NULL
access	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
APL	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
24CG	NULL
mice	NULL
did	NULL
display	NULL
a	NULL
preleukemic	NULL
state	NULL
that	NULL
eventually	NULL
progressed	NULL
to	NULL
overt	NULL
leukemia	NULL
,	NULL
but	NULL
they	NULL
nevertheless	NULL
differed	NULL
in	NULL
several	NULL
substantive	NULL
regards	NULL
from	NULL
the	NULL
hMRP3	NULL
mice	NULL
described	NULL
in	NULL
the	NULL
present	NULL
communication	NULL
.	NULL

The	NULL
leukemias	NULL
in	NULL
ACG	NULL
mice	NULL
were	NULL
accompanied	NULL
by	NULL
elevated	NULL
white	NULL
blood	NULL
cell	NULL
counts	NULL
and	NULL
the	NULL
persistence	NULL
of	NULL
maturing	NULL
neutrophils	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
and	NULL
treatment	NULL
with	NULL
ATRA	NULL
caused	NULL
apoptosis	NULL
rather	NULL
than	NULL
differentiation	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
.	NULL

Several	NULL
factors	NULL
may	NULL
figure	NULL
in	NULL
these	NULL
differences	NULL
.	NULL

The	NULL
AMRPS	NULL
gene	NULL
is	NULL
expressed	NULL
more	NULL
broadly	NULL
in	NULL
the	NULL
myeloid	NULL
lineage	NULL
than	NULL
hCG	NULL
,	NULL
which	NULL
is	NULL
restricted	NULL
to	NULL
promyelocytes	NULL
and	NULL
promonocytes	NULL
(	NULL
39	NULL
)	NULL
.	NULL

The	NULL
hCG	NULL
transgene	NULL
may	NULL
be	NULL
down-regulated	NULL
following	NULL
ATRA	NULL
treatment	NULL
,	NULL
while	NULL
expression	NULL
from	NULL
the	NULL
hAMRPS8	NULL
promoter	NULL
is	NULL
maintained	NULL
during	NULL
neutrophilic	NULL
differentiation	NULL
.	NULL

The	NULL
genetic	NULL
backgrounds	NULL
of	NULL
the	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
2555	NULL
transgenic	NULL
mice	NULL
also	NULL
differ	NULL
,	NULL
which	NULL
could	NULL
affect	NULL
the	NULL
response	NULL
to	NULL
PMLRARa	NULL
expression	NULL
:	NULL
the	NULL
hCG	NULL
mice	NULL
were	NULL
made	NULL
in	NULL
(	NULL
C57BL/	NULL
6	NULL
x	NULL
C3H/He	NULL
)	NULL
F	NULL
»	NULL
cross	NULL
mice	NULL
,	NULL
whereas	NULL
the	NULL
hMRPS	NULL
mice	NULL
were	NULL
made	NULL
in	NULL
inbred	NULL
FVB/N	NULL
mice	NULL
.	NULL

In	NULL
yet	NULL
another	NULL
experimental	NULL
approach	NULL
,	NULL
an	NULL
avian	NULL
retrovirus	NULL
was	NULL
used	NULL
to	NULL
express	NULL
PMLRARa	NULL
«	NULL
in	NULL
chicken	NULL
embryos	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
result	NULL
was	NULL
an	NULL
acute	NULL
leukemia	NULL
composed	NULL
of	NULL
multipotent	NULL
blast	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
far	NULL
less	NULL
mature	NULL
than	NULL
the	NULL
promyelocytes	NULL
of	NULL
APL	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
blasts	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
ATRA	NULL
,	NULL
and	NULL
their	NULL
occurrence	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
consistent	NULL
pair	NULL
of	NULL
mutations	NULL
in	NULL
the	NULL
PML	NULL
moiety	NULL
of	NULL
the	NULL
fusion	NULL
gene	NULL
,	NULL
mutations	NULL
that	NULL
have	NULL
not	NULL
been	NULL
reported	NULL
to	NULL
occur	NULL
in	NULL
human	NULL
patients	NULL
.	NULL

While	NULL
this	NULL
system	NULL
did	NULL
reveal	NULL
that	NULL
PMLRARa	NULL
has	NULL
leukemogenic	NULL
potential	NULL
outside	NULL
a	NULL
promyelocytic	NULL
context	NULL
,	NULL
the	NULL
recurrent	NULL
mutations	NULL
and	NULL
nonpro-myelocytic	NULL
character	NULL
of	NULL
the	NULL
leukemic	NULL
blasts	NULL
distinguish	NULL
it	NULL
from	NULL
human	NULL
APL	NULL
.	NULL

The	NULL
strong	NULL
correspondence	NULL
between	NULL
human	NULL
APL	NULL
and	NULL
the	NULL
murine	NULL
leukemia	NULL
described	NULL
here	NULL
indicates	NULL
that	NULL
the	NULL
hMRPS-PMLRARa	NULL
system	NULL
can	NULL
be	NULL
used	NULL
to	NULL
obtain	NULL
information	NULL
that	NULL
is	NULL
directly	NULL
relevant	NULL
to	NULL
the	NULL
human	NULL
disease	NULL
.	NULL

The	NULL
transgenic	NULL
mice	NULL
provide	NULL
a	NULL
valuable	NULL
tool	NULL
for	NULL
further	NULL
exploring	NULL
the	NULL
mechanisms	NULL
of	NULL
PmlRara	NULL
action	NULL
,	NULL
for	NULL
isolating	NULL
the	NULL
additional	NULL
genetic	NULL
events	NULL
that	NULL
collaborate	NULL
with	NULL
PMLRARa	NULL
to	NULL
induce	NULL
acute	NULL
disease	NULL
,	NULL
and	NULL
for	NULL
exploring	NULL
therapeutic	NULL
approaches	NULL
that	NULL
may	NULL
improve	NULL
the	NULL
survival	NULL
of	NULL
patients	NULL
with	NULL
APL	NULL
and	NULL
other	NULL
leukemias	NULL
.	NULL

We	NULL
thank	NULL
K.	NULL
Chang	NULL
for	NULL
anti-Pml	NULL
antiserum	NULL
and	NULL
M.	NULL
Lanotte	NULL
for	NULL
providing	NULL
NB4	NULL
cells	NULL
,	NULL
members	NULL
of	NULL
the	NULL
Bishop	NULL
lab	NULL
for	NULL
helpful	NULL
advice	NULL
and	NULL
discussion	NULL
,	NULL
D.	NULL
Hanahan	NULL
for	NULL
teaching	NULL
D.B	NULL
.	NULL

how	NULL
to	NULL
make	NULL
and	NULL
care	NULL
for	NULL
transgenic	NULL
mice	NULL
,	NULL
M.	NULL
Pallavicini	NULL
for	NULL
teaching	NULL
murine	NULL
bone	NULL
marrow	NULL
transplantation	NULL
to	NULL
S.K	NULL
,	NULL
and	NULL
T.	NULL
Ley	NULL
for	NULL
communication	NULL
of	NULL
results	NULL
prior	NULL
to	NULL
publication	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
CA	NULL
44338	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
and	NULL
by	NULL
funds	NULL
from	NULL
the	NULL
G.	NULL
W.	NULL
Hooper	NULL
Research	NULL
Foundation	NULL
(	NULL
to	NULL
J.M.B	NULL
.	NULL
)	NULL

.	NULL

S.K	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
physician	NULL
fellowships	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
and	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
.	NULL

1	NULL
.	NULL

Rowley	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Golomb	NULL
,	NULL
H.	NULL
M.	NULL
&	NULL
Dougherty	NULL
,	NULL
C.	NULL
(	NULL
1977	NULL
)	NULL
Lancet	NULL
i	NULL
,	NULL
549-550	NULL
.	NULL

2	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Wang	NULL
,	NULL
Z.	NULL
Y	NULL
.	NULL

&	NULL
Degos	NULL
,	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

329	NULL
,	NULL
177-189	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Longo	NULL
,	NULL
L.	NULL
,	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Donti	NULL
,	NULL
E.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
Blood	NULL
83	NULL
,	NULL
10-25	NULL
.	NULL

4.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
347	NULL
,	NULL
558-561	NULL
.	NULL

5	NULL
.	NULL

Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
,	NULL
Jr.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Warrell	NULL
,	NULL
R.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Murty	NULL
,	NULL
V.	NULL
V.	NULL
,	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
663-674	NULL
.	NULL

6	NULL
.	NULL

Chang	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Fan	NULL
,	NULL
Y.	NULL
H.	NULL
,	NULL
Andreeff	NULL
,	NULL
M.	NULL
,	NULL
Liu	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Mu	NULL
,	NULL
Z.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
85	NULL
,	NULL
3646-3653	NULL
.	NULL

7	NULL
.	NULL

Huang	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Ye	NULL
,	NULL
Y.	NULL
C.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Zhao	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Gu	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Cai	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Zhao	NULL
,	NULL
L.	NULL
,	NULL
Xie	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Shen	NULL
,	NULL
Z.	NULL
X	NULL
.	NULL

&	NULL
Wang	NULL
,	NULL
Z.	NULL
Y	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Chin	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

(	NULL
Engl	NULL
.	NULL
)	NULL

100	NULL
,	NULL
949-953	NULL
.	NULL

8	NULL
.	NULL

Warrell	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Scheinberg	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Itri	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Hittelman	NULL
,	NULL
W.	NULL
N.	NULL
,	NULL
Vyas	NULL
,	NULL
R.	NULL
,	NULL
Andreeff	NULL
,	NULL
M.	NULL
,	NULL
Tafuri	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Jakubowski	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

324	NULL
,	NULL
1385-1393	NULL
.	NULL

9.	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Marchio	NULL
,	NULL
A.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
675-684	NULL
.	NULL

10	NULL
.	NULL

-	NULL
Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
LoCoco	NULL
,	NULL
F.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
1285-1292	NULL
.	NULL

11	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
Perez	NULL
,	NULL
A.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Rochette	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
&	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
629-642	NULL
.	NULL

12	NULL
.	NULL

Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Koken	NULL
,	NULL
M.	NULL
,	NULL
Romagne	NULL
,	NULL
O.	NULL
,	NULL
Barbey	NULL
,	NULL
S.	NULL
,	NULL
Bazarbachi	NULL
,	NULL
A.	NULL
,	NULL
Stadler	NULL
,	NULL
M.	NULL
,	NULL
Guillemin	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
&	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
82	NULL
,	NULL
1858-1867	NULL
.	NULL

13	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Ferrucci	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Talamo	NULL
,	NULL
G.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Peschle	NULL
,	NULL
C.	NULL
,	NULL
Nicoletti	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
74	NULL
,	NULL
423-431	NULL
.	NULL

14	NULL
.	NULL

Perez	NULL
,	NULL
A.	NULL
,	NULL
Kastner	NULL
,	NULL
P.	NULL
,	NULL
Sethi	NULL
,	NULL
S.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Reibel	NULL
,	NULL
C.	NULL
&	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
3171-3182	NULL
.	NULL

2556	NULL
15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

Dyck	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Maul	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
333-343	NULL
.	NULL

Rousselot	NULL
,	NULL
P.	NULL
,	NULL
Hardas	NULL
,	NULL
B.	NULL
,	NULL
Patel	NULL
,	NULL
A.	NULL
,	NULL
Guidez	NULL
,	NULL
F.	NULL
,	NULL
Gaken	NULL
,	NULL
J.	NULL
,	NULL
Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Dejean	NULL
,	NULL
A.	NULL
,	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
Farzanch	NULL
,	NULL
F.	NULL
&	NULL
Chomienne	NULL
,	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
545-551	NULL
.	NULL

Weis	NULL
,	NULL
K.	NULL
,	NULL
Rambaud	NULL
,	NULL
S.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Jansen	NULL
,	NULL
J.	NULL
,	NULL
Carvalho	NULL
,	NULL
T.	NULL
,	NULL
Carmo-Fonseca	NULL
,	NULL
M.	NULL
,	NULL
Lamond	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
345-356	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Barberi	NULL
,	NULL
T.	NULL
,	NULL
Masciulli	NULL
,	NULL
R.	NULL
,	NULL
Mariani	NULL
,	NULL
G.	NULL
,	NULL
Peschle	NULL
,	NULL
C.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Cancer	NULL
Res	NULL
55	NULL
,	NULL
440-443	NULL
.	NULL

Borrow	NULL
,	NULL
J.	NULL
,	NULL
Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Gibbons	NULL
,	NULL
B.	NULL
,	NULL
Katz	NULL
,	NULL
F.	NULL
,	NULL
Swirsky	NULL
,	NULL
D.	NULL
,	NULL
Fioretos	NULL
,	NULL
T.	NULL
,	NULL
Dube	NULL
,	NULL
I.	NULL
,	NULL
Winfield	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Kingston	NULL
,	NULL
J.	NULL
,	NULL
Hagemeijer	NULL
,	NULL
A.	NULL
,	NULL
Rees	NULL
,	NULL
J.	NULL
K.	NULL
H.	NULL
,	NULL
Lister	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

&	NULL
Solomon	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

82	NULL
,	NULL
529-540	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Diverio	NULL
,	NULL
D.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Lo	NULL
Coco	NULL
,	NULL
F.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Grignani	NULL
,	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
1397-1407	NULL
.	NULL

Lagasse	NULL
,	NULL
E.	NULL
&	NULL
Weissman	NULL
,	NULL
I.	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179	NULL
,	NULL
1047-1052	NULL
.	NULL

Hogan	NULL
,	NULL
B.	NULL
,	NULL
Constantini	NULL
,	NULL
F.	NULL
&	NULL
Lacy	NULL
,	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
Manipulating	NULL
the	NULL
Mouse	NULL
Embryo	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

Press	NULL
,	NULL
Plainview	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Taketo	NULL
,	NULL
M.	NULL
,	NULL
Schroeder	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Mobraaten	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Gunning	NULL
,	NULL
K.	NULL
B.	NULL
,	NULL
Hanten	NULL
,	NULL
G.	NULL
,	NULL
Fox	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Roderick	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Stewart	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Lilly	NULL
,	NULL
F.	NULL
,	NULL
Hansen	NULL
,	NULL
C.	NULL
T.	NULL
&	NULL
Overbeck	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
2065-2969	NULL
.	NULL

Coligan	NULL
,	NULL
J.	NULL
,	NULL
Kruisbeck	NULL
,	NULL
A.	NULL
,	NULL
Margulies	NULL
,	NULL
D.	NULL
,	NULL
Shevach	NULL
,	NULL
E.	NULL
,	NULL
Strober	NULL
,	NULL
W.	NULL
,	NULL
eds	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Current	NULL
Protocols	NULL
in	NULL
Immunology	NULL
(	NULL
Greene/Wiley	NULL
Interscience	NULL
,	NULL
New	NULL
York	NULL
)	NULL
.	NULL

pp	NULL
.	NULL

3.1.3-3.1.5	NULL
.	NULL

Robbins	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Quintrell	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

&	NULL
Bishop	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
3507-3515	NULL
.	NULL

Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Rochette-Egly	NULL
,	NULL
C.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Ali	NULL
,	NULL
S.	NULL
,	NULL
Matthes	NULL
,	NULL
H.	NULL
,	NULL
Scheuer	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Chambon	NULL
,	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

201	NULL
,	NULL
335-346	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
(	NULL
1997	NULL
)	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Martin-Thouvenin	NULL
,	NULL
V.	NULL
,	NULL
Najman	NULL
,	NULL
S.	NULL
,	NULL
Balerini	NULL
,	NULL
P.	NULL
,	NULL
Valensi	NULL
,	NULL
F.	NULL
&	NULL
Berger	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
1080-1086	NULL
.	NULL

Dalton	NULL
,	NULL
W.	NULL
T.	NULL
,	NULL
Jr.	NULL
,	NULL
Abearn	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
McCredie	NULL
,	NULL
K.	NULL
B.	NULL
,	NULL
Freireich	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Stass	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

&	NULL
Trujillo	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Blood	NULL
71	NULL
,	NULL
242-247	NULL
.	NULL

Fleming	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Fleming	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Malek	NULL
,	NULL
T.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
2399-2408	NULL
.	NULL

Hestdal	NULL
,	NULL
K.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Ihle	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Jacobsen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Dubois	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Kopp	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
&	NULL
Keller	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
22-28	NULL
.	NULL

Knowles	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Neoplastic	NULL
Hematopathology	NULL
(	NULL
Williams	NULL
&	NULL
Wilkins	NULL
,	NULL
Baltimore	NULL
)	NULL
.	NULL

Davey	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
Davis	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
MacCallum	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Nelson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Mayer	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Ball	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
Griffin	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Schiffer	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Bloom-field	NULL
,	NULL
C.	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Hematol	NULL
.	NULL

30	NULL
,	NULL
221-227	NULL
.	NULL

Paictta	NULL
,	NULL
E.	NULL
,	NULL
Andersen	NULL
,	NULL
J.	NULL
,	NULL
Gallagher	NULL
,	NULL
R.	NULL
,	NULL
Bennett	NULL
,	NULL
J.	NULL
,	NULL
Yunis	NULL
,	NULL
J.	NULL
,	NULL
Cassileth	NULL
,	NULL
P.	NULL
,	NULL
Rowe	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Wiernik	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
Leukemia	NULL
8	NULL
,	NULL
1108-1112	NULL
.	NULL

Muindi	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Young	NULL
,	NULL
C.	NULL
W.	NULL
&	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
(	NULL
1994	NULL
)	NULL
Leukemia	NULL
8	NULL
(	NULL
Suppl	NULL
.	NULL

3	NULL
)	NULL
,	NULL
S16-S21	NULL
.	NULL

Achkar	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Bentel	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Boylan	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Scher	NULL
,	NULL
H.	NULL
I.	NULL
,	NULL
Gudas	NULL
,	NULL
L.	NULL
J	NULL
.	NULL

&	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
(	NULL
1994	NULL
)	NULL
Drug	NULL
Metab	NULL
.	NULL

Dispos	NULL
.	NULL

22	NULL
,	NULL
451-458	NULL
.	NULL

Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Eardley	NULL
,	NULL
A.	NULL
,	NULL
Lauwers	NULL
,	NULL
G.	NULL
,	NULL
Weiss	NULL
,	NULL
M.	NULL
&	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
(	NULL
1992	NULL
)	NULL
Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

117	NULL
,	NULL
292-296	NULL
.	NULL

Early	NULL
,	NULL
E.	NULL
,	NULL
Moore	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Nason-Burchenal	NULL
,	NULL
K.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
,	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Nail	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
,	NULL
7900-7904	NULL
.	NULL

Grisolano	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Wesselschmidt	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
&	NULL
Ley	NULL
,	NULL
T.	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
Blood	NULL
89	NULL
,	NULL
376-387	NULL
.	NULL

Grisolano	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Sclar	NULL
,	NULL
G.	NULL
M.	NULL
&	NULL
Ley	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
8989-8993	NULL
.	NULL

Altabef	NULL
,	NULL
M.	NULL
,	NULL
Garcia	NULL
,	NULL
M.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Bae	NULL
,	NULL
S.-C.	NULL
,	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Samarut	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
2707-2716	NULL
.	NULL

